Emerging Strategies in Dyslipidemia Management

PROGRAM DESCRIPTION This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes by accelerating adoption of new guidelines and evidence-based practice ...

PROGRAM DESCRIPTION
This webcast is intended to improve care of dyslipidemia in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

EDUCATIONAL OBJECTIVES
As a result of participating in the activity, learners should be better able to: Outline risk assessment tools to identify dyslipidemia patients who may benefit from further reduction in low-density lipoprotein-cholesterol (LDL-C)Assess the impact of PCSK9 inhibitors evolocumab and alirocumab on LDL-C and cardiovascular risk in patients with atherosclerotic cardiovascular disease, familial hypercholesterolemia, and diabetes

---

Write the first review

Resource tags